Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- (-) Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 83 Results
What's It Like to Be an NPC Fellow?
Our current and previous fellows share some inside tips
Current Landscape: Value Assessment Frameworks
This report analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework.
Second National Pharmaceutical Council and Health Affairs Forum to Explore Emerging Health Spending Solutions
NPC, Health Affairs and several Going Below The Surface Forum partners on Sept. 11 are hosting a discussion among health policy experts on emerging solutions to rising U.S. health spending
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
NPC in Chain Drug Review: The Long-term Health Benefits of Biopharmaceuticals
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care…
Tackling Low-Value Care Will Take a Group Effort
During a briefing with partners of the Going Below The Surface Forum, three leaders in the effort to reduce low-value care in the United States explained why this has been such a tough challenge to…
NPC in Specialty Pharmacy Times: How Can We Advance Progress in Moving from Volume to Value in Health Care?
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a…
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?
In this study from the National Pharmaceutical Council and IQVIA, researchers developed a model to understand the underlying methodological inputs that drive the substantial variation in drug…
Study Finds That Costs Dropped, Outcomes Improved for Major Causes of Death and Illness Between 1995 and 2015
Spending for six of the top seven causes of death and disease over the last 20 years was both cost-effective and improved patient outcomes, according to a study from NPC and RTI Health Solutions…
Get to Know Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD
Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD, sat down with us to discuss her upcoming research, bridging the gap between academia and health care stakeholders, tips for…